Pharmaceutical Technologies

The following section deals with manufacturing technologies of Pharmaceuticals and up-to-date pharmaceutical equipment

A Russian vaccine against Haemophilus influenzae

This year, the Ministry of Health of the Russian Federation may increase the list of risk groups for mandatory vaccination against infections caused by Haemophilus influenzae. There is no local drug o...

Announced the launch of the Unified Website for Biotechnology Regulation

The U.S. Food and Drug Administration, the Department of Agriculture and the Environmental Protection Agency launched a Unified Website for Biotechnology Regulation. The website streamlines informatio...

A Russian drug gets Alzheimer’s patients to recover the memory

Scientists of the Competence Center of National Technological Initiative (NTI according to Russian abbreviation) are developing a drug based on a fragment of the human protein Lynx1, which recovers th...
drug-development

HHS, ASPR, BARDA Award Paratek 5-Year Contract for NUZYRA®

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced that the Department of Health and Hum...

3P Biopharmaceuticals, In3Bio to Collaborate in Novel Anti-Tumor Treatment Development

3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based bi...
viiv healthcare

ViiV Healthcare, Pfizer and Shionogi Announced Development of Investigational Antibody N6LS

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the company will be developing the investigation...
drug-development

FDA Policies on Drug Development Analyzed by Experts

The US Food and Drug Administration (FDA) heard from more than two dozen stakeholders on opportunities for the agency to promote more effective drug development programs at a public workshop at its he...
regeneron

Regeneron Pharmaceuticals Updated on Phase III Development Program of Libtayo®

Regeneron Pharmaceuticals, Inc. provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line p...

Video

Expert opinion